Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2020

View Archived Issues

RNA editing restores Rett protein

Single-cell studies give insights into pulmonary fibrosis

CD63 expression confers poor survival in patients with ESCC

Starvation safety switch could make cell therapies safer

Discovery of PQR-626, a potent and brain-penetrant mTOR inhibitor

HLJ1 as a potential new therapeutic target and biomarker in HCC

Intra-Cellular Therapies identifies 5-HT2A, mu-opioid, dopamine D1 and D2 receptor ligands

New RIP-2 inhibitors discovered at Celgene

KSQ Therapeutics presents new ubiquitin carboxyl-terminal hydrolase 1 inhibitors

RCC2 blockade is a potential therapeutic approach in glioblastoma

Sage Therapeutics describes GABA-A receptor modulators

Roche patents antibacterials

First child dosed in phase II study of infigratinib in achondroplasia

Novocure and MSD to study Tumor Treating Fields with Keytruda in NSCLC

Can-Fite amends phase II COVID-19 study protocol based on FDA guidance

Byondis initiates phase II study of SYD-985 in advanced endometrial cancer

Zydus begins human dosing with ZyCoV-D vaccine

CS-3003, an HDAC6 inhibitor, shows promise for treating multiple myeloma

FDA clears IND for clinical evaluation of long-acting human IL-7 NT-17 for mild COVID-19

RBM-007 enters phase I study for treatment of achondroplasia

Octapharma reports on use of Octagam IVIG in critically ill patients with COVID-19

BioAegis cleared to begin phase II study of rhu-pGSN in severe COVID-19 pneumonia

Bold Therapeutics reports promising in vitro data on BOLD-100 for COVID-19

Phase II study of GT-005 begins enrolling patients with GA secondary to AMD

First-in-human study of SL-172154 in ovarian cancer starts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...